Aurora Cannabis (ACB) Other Non-Current Liabilities (2018 - 2025)
Aurora Cannabis (ACB) posted quarterly Other Non-Current Liabilities of $1.3 million for Q4 2025, down 68.71% year-on-year from $4.1 million in Q4 2024, and down 1.98% on a QoQ basis from $1.3 million in Q3 2025.
Aurora Cannabis (ACB) Other Non-Current Liabilities (2018 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Other Non-Current Liabilities for 8 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 68.71% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 68.71% YoY) and the FY2025 annual result came in at $1.2 million, down 70.8% from the prior year.
- Other Non-Current Liabilities declined to $1.3 million in Q4 2025 per ACB's latest filing, from $1.3 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ACB reached as high as $4.2 million in Q2 2022 and fell as low as $502106.4 in Q1 2022.
- A 5-year average of $2.7 million and a median of $2.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities soared 774.11% — and 2025, when it slumped 71.71%.
- Year by year, Other Non-Current Liabilities stood at $2.0 million in 2021, then soared by 30.46% to $2.6 million in 2022, then jumped by 48.7% to $3.8 million in 2023, then gained by 6.69% to $4.1 million in 2024, then tumbled by 68.71% to $1.3 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.3 million, $1.3 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 4.07 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | 4.24 Mn |
| Mar 31, 2024 | 4.16 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Sep 30, 2023 | 3.71 Mn |
| Jun 30, 2023 | 3.50 Mn |
| Mar 31, 2023 | 3.29 Mn |
| Dec 31, 2022 | 2.56 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | 4.24 Mn |
| Mar 31, 2022 | 502,106.36 |
| Dec 31, 2021 | 1.97 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | 1.69 Mn |
| Mar 31, 2021 | 1.58 Mn |